Abstracts insurance, physician type, region, pre-dialysis co-morbidities, and pre-dialysis costs were used to evaluate the impact of pre-dialysis paricalcitol treatment on hospitalizations, outpatient services, and medication use in first year of dialysis. RESULTS: Multivariable analysis demonstrated predialysis paricalcitol use was associated with statistically significant reductions in all-cause hospitalizations (0.806, 95%CI: 0.684-0.950), all-cause outpatient services (0.953, 95%CI: 0.933-0.973) and CKDrelated hospitalizations (0.780, 95% CI: 0.635 -0.958); CKD-related outpatient visits (0.962, 95% CI: 0.938-0.987); and CKD-related medications (0.922, 95% CI: 0.852-0.996) in the first year of dialysis compared with no predialysis VDR activator treatment. CONCLUSIONS: Paricalcitol treatment for SHPT prior to dialysis is associated with fewer CKD-related medications; and all-cause and CKD-related outpatient services and hospitalizations in the first year of dialysis compared to no VDR activator treatment. Payers should consider these findings when make coverage decisions regarding the use of paricalcitol. Further studies are needed to confirm these results. OBJECTIVES: The Combination of Avodart ® and Tamsulosin (CombAT) study shows that combination therapy provides a significantly greater degree of benefit than tamsulosin or dutasteride monotherapy in the treatment of moderate to severe benign prostatic hyperplasia (BPH). The objective of this study was to assess the cost-effectiveness of combination therapy with tamsulosin and dutasteride relative to either of monotherapies using recent information from the CombAT study. METHODS: A decision analytic model was constructed using a Markov model and a 1-year cycle time to estimate the clinical and cost consequences of tamsulosin, dutasteride, and combination therapy. Analyses were conducted for a 20-year time frame from the societal perspective. All costs are presented in 2009 US dollars, and costs and outcomes were discounted at a rate of 3% per year. Outcomes were expressed in terms of the incremental cost-effectiveness ratio (ICER), defined as the ratio of additional costs to additional QALYs. Sensitivity analyses were conducted on model probabilities, cost estimates, utility values and the discount rate. RESULTS: At both moderate and severe symptom levels, tamsulosin was dominated by dutasteride, that is, more costly and less effective than dutasteride. Compared to dutasteride, combination therapy was more expensive but more effective with the ICERs of $197,625 for moderate symptoms and $241,032 for severe symptoms. However, considering a societal cost-effectiveness threshold of $150,000 per QALY, combination therapy was not cost-effective compared to dutasteride. In most sensitivity analyses, these results were not sensitive to changes in model parameters. CONCLUSIONS: This study showed that tamsulosin was more costly and less effective than dutasteride, and the ICERs for combination therapy compared to dutasteride were higher than the cost-effectiveness threshold. Therefore, combination therapy is not cost-effective relative to dutasteride for moderate-to-severe BPH patients.
considerable negative impact on quality of life. The cost-effectiveness (CE) of three medications was evaluated for the treatment of patients with Hyperactive Bladder from the Mexican Institute of Social Security (IMSS) perspective. METHODS: CE analysis from the perspective of the service provider (IMSS). Since it is a chronic disease with different stages, a Markov model with monthly cycles in a 12-month temporal horizon was developed. Only direct medical costs were used in the analysis. Direct medical costs were estimated on a sample of patient files in two IMSS medical units. Criteria for inclusion was patients with more than 6 months of treatment. The effectiveness measurement was taken from literature and was defined as the percentage of patients that did not present symptoms of incontinence. Univariated and probabilistic sensitivity analyses were performed. RESULTS: The oxybutynin treatment reflected the lowest expected cost per patient treated for hyperactive bladder, US$545 (1 USD = 13.5MXN); followed by the solifenacin and tolterodine treatments, with a cost of US$680 and US$1,135, respectively. As for the effectiveness measurement, the percentage of patients that did not present incontinence within the temporal horizon of analysis was: with tolterodine 2.76%, with oxybutynin 7.11% and with solifenacin 7.46%. Therefore, cost effectiveness ratios interpreted as the cost per percentage point of patients that did not present HB are: oxybuynin US$77, solifenacin US$91 and tolterodine US$411. The incremental cost effectiveness analysis indicates that tolterodine is a dominated alternative and that oxybutynin and solifenacin are positioned within the efficiency line. Nonetheless, when conducting the probabilistic analysis, it was found that with US$411 available, a solifenacin treatment would be more cost effective for the institution. CONCLUSIONS: From an institutional perspective, solifenacine is a cost-effective alternative for treating patients with HB in the Mexican context.
PUK13 THE COST-EFFECTIVENESS OF EARLY SURGERY, ADDING BIOPSY, AND WATCHFUL WAITING IN THE MANAGEMENT OF SMALL SOLID RENAL MASSES: EVIDENCE FROM A MARKOV MODEL
Yu J 1 , Heilbrun M 1 , Smith K 2 , Zagoria R 3 1 University of Utah, Salt lake city, UT, USA, 2 University of Pittsburgh, Pittsburgh, PA, USA, 3 Wake Forest University, Winston-Salem, NC, USA OBJECTIVES: To compare the relative cost-effectiveness of three clinical strategies for managing T1a tumor (4 cm or smaller and limited to the kidney): early surgery upon detection of the tumor, adding percutaneous biopsy prior to surgery, and watchful waiting (WW) (monitor with computerized tomography every 6 months until the growth is greater than 2mm per year). METHODS: A Markov decision tree was used to estimate the expected survival in quality-adjusted life years (QALYs) and incremental cost-effectiveness (ICER) for each strategy from a societal perspective, based on literature-derived estimates for the probabilities and costs of different outcomes. Multiple one-way and probabilistic sensitivity analysis were conducted to examine the robustness of the results. RESULTS: In the base-case, adding biopsy before surgery improved survival by 0.018 QALYs compared with immediate surgery, at an incremental cost of $55,244/QALY, while the ICER of WW relative to surgery was $11,712/QALY. In the base-case, percutaneous biopsy is more expensive and less effective than WW. The treatment decision was most sensitive to variation of the degree of tumor growth that triggers surgery, utility of living with a mass during WW, and the probability of diagnostic biopsy for benign tumors. Choice of WW versus surgery critically depends on patients' preferences for tumor removal and the risk of recurrence post surgery. In probabilistic sensitivity analysis, surgery was the most favored strategy when the willingness to pay (WTP) is less than $10,000/QALY. WW is favored as WTP increases beyond $10,000/QALY, and biopsy was favored over surgery when WTP is > $60,000. CONCLUSIONS: Although WW results in the highest life-time utility, the favorability of WW depends on patients' preferences for living with a possibly malignant mass and natural history of watched masses during surveillance, which are poorly understood. Biopsy would be favored if its costs decrease and diagnostic certainty increases in the future.
PUK14 CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS: A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA
Grima D 1 , Mendelssohn D 2 , Airia P 1 , Dunn E 3 , Bernard L 1 1 Cornerstone Research Group Inc., Burlington, ON, Canada, 2 Humber River Regional Hospital, Weston, ON, Canada, 3 Genzyme Corporation, Cambridge, MA, USA OBJECTIVES: Therapies that extend the lives of dialysis patients can not demonstrate cost-effectiveness if dialysis costs are included. This study examined the cost-effectiveness of sevelamer versus calcium-based binders (CBBs) as treatment for hyperphosphatemia in dialysis patients and, within this context, the suitability of the inclusion of dialysis costs. METHODS: A Markov model estimated life years, incremental cost per life year gained (LYG) and incremental quality-adjusted life year gained (QALYG). Treatment-specific survival was derived from the Dialysis Clinical Outcomes Revisited (DCOR) study and extrapolated using a Weibull regression model. The base case analysis used resource use and survival data for DCOR patients ≥65 years combined with Canadian unit costs and utility weights from published literature. Dialysis costs were excluded from the base case analysis, as dialysis use is unrelated to phosphate binder choice. Analyses were conducted for a 10-year time horizon using the Alberta Health Care System perspective, with costs and outcomes discounted at 5% per year. RESULTS: Compared with CBBs, sevelamer resulted in a gain of 1.02 LYs and 0.62 QALYs/ patient (discounted) producing ratios of $20,847/LYG and $34,175/ QALYG. Over a lifetime horizon, the cost/LYG and cost/QALYG were $23,804 and $39,022, respectively. Inclusion of dialysis costs resulted in ratios above $90,000/LYG and $150,000/QALYG. CONCLUSIONS: The study highlights the challenges associated with assessing funding of therapies that extend life in dialysis patients and discusses the applicability of dialysis costs in such situations. It found that sevelamer offers good value for money compared to CBBs in the treatment of hyperphosphatemia in patients ≥65 years old receiving dialysis.
PUK15

COST-EFFECTIVENESS ANALYSIS OF THREE MONTHS TREATMENT WITH FESOTERODINE COMPARED TO GENERIC OXYBUTYNIN EXTENDED-RELEASE IN WOMEN WITH URINARY INCONTINENCE FROM A THIRD PARTY PAYER PERSPECTIVE
Blaser DA 1 , Kohn MJ 2 , Ousterhout M 1 1 UMass Medical School, Shrewsbury , MA, USA, 2 Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA OBJECTIVES: Six pharmacological agents are FDA-approved to treat urinary incontinence, a condition that has economic costs of $19 billion US dollars per year. This study compares the recently FDA-approved fesoterodine to generic oxybutynin extended-release (ER) to identify which agent is more cost-effective in the treatment of urinary incontinence for three months in women over age 60 from the third party payer perspective. METHODS: A search was conducted using the MEDLINE Database from 1980-2009 for the terms "oxybutynin," "fesoterodine," "randomized controlled trial," and "urinary incontinence." Five articles evaluating clinical improvement among a predominantly female population were identified for inclusion. For the purpose of this analysis, an effectively treated patient was defined as a patient demonstrating a decrease of 14 or more episodes per week of each of the following: urge incontinence, total incontinence, and micturitions. Using Z-scores, the percentage of effectively treated patients was calculated for both fesoterodine and generic oxybutynin ER. Costs included a physician visit for patients failing treatment and the average wholesale price of each medication in 2009 US dollars. Data and costs associated with each treatment arm were entered into TreeAge Pro 2008 to obtain the cost-effectiveness ratios for both therapies. RESULTS: Overall cost-effectiveness ratios obtained were $375.27 ($297.59/0.793) per effectively treated patient with oxybutynin ER compared to $641.67 ($435.01/0.678) per effectively treated patient with fesoterodine. Due to the greater effect and lower cost of oxybutynin ER, an incremental costeffectiveness ratio was not necessary. Sensitivity analyses revealed the results to be most sensitive to changes in the probability of oxybutynin ER resulting in an effectively treated patient. CONCLUSIONS: Based on this decision model, oxybutynin ER is the dominant treatment. Third-party payers may want to consider making oxybutynin ER a preferred option for their formularies, rather than fesoterodine.
PUK16
COST-EFFECTIVENESS ANALYSIS IN TREATING OVERACTIVE BLADDER WITH URGE INCONTINENCE IN WOMEN: A COMPARISON BETWEEN OXYBUTYNIN AND TOLTERODINE WITH EXPLORATORY ANALYSIS OF FESOTERODINE
Schwartz EL, Hay JW University of Southern California, Los Angeles, CA, USA OBJECTIVES: Overactive bladder (OAB) disease with urinary incontinence is a prevalent disorder among millions of women reaping both high burdens in treatment costs and in health-related quality of life. Oxybutynin ER and tolterodine ER are two anticholinergic therapies that have demonstrated efficacy, but have significant adverse event profiles contributing to long-term discontinuation. No current cost-effectiveness analysis has compared these two therapies to the recent release of an additional anticholinergic medication, fesoterodine. With three drugs and numerous possible drug regimens involving switching between medications, there exists need for economic analysis of the costs and QALYs for OAB treatment. The objective of this study was to conduct CE analysis using a backwards induction model to compare costs and quality-adjusted life years (QALYs) for the following drug regimens: oxybutynin ER, tolterodine ER, fesoterodine, oxybutynin switch tolterodine, tolterodine switch oxybutynin, and fesoterodine switch tolterodine. METHODS: The CE model costs were derived using a societal perspective. The analysis was conducted in women with OAB over the age of 45 years old experiencing urinary incontinence and used valued literature sources of clinical, cost and compliance data. RESULTS: Based on the model inputs, the ICER comparing fesoterodine to tolterodine is $65,880/QALY indicating that at the current branded price and base case data on clinical effectiveness and compliance, fesoterodine is the most cost-effective treatment. Sensitivity and threshold analysis indicate that these results are sensitive to changes in the following inputs: utility values for adverse events and medication discontinuation rates. With changes in these values of 15% and 25 % respectively, tolterodine ER is the most cost-effective treatment. CONCLUSIONS: Drug treatment for OAB with urinary incontinence in this population with fesoterodine is most cost-effective when compared to other anticholingerics and switching regimens. Limitations of this study include data on compliance and utility values, which the model is sensitive to.
PUK17 THE VALUE OF HYPERTENSION CONTROL TO CHRONIC KIDNEY DISEASE PREVENTION
Zhuo X 1 , Keeler E 2 , Wu S 2 , Vargas R 2 1 RAND Graduate School, Atlanta, GA, USA, 2 RAND Corporation, Santa Monica, CA, USA OBJECTIVES: We assessed the potential health and economic benefits of reducing the main chronic kidney disease risk factor-hypertension. METHODS: A chronic kidney disease microsimulation model tracked a nationally representative cohort to project their chronic kidney disease outcomes over thiry years in a hypothetical scenario that hypertension could be effectively reduced among the cohort. RESULTS: An effective hypertension control saved both cost and lives. Relative to status quo, the gain in quality adjusted life years from the improved hypertension adherence would be 1.28 QALYs within 30 years. The total medical cost saving was estimated to be $789 per capita, largely due to the substantial savings from the downstream spending on end stage renal disease. A total of 224 thousand cases of ESRD, 368 thousand cases of renal transplant and 248 thousands cardiovascular events could be avoided due to the better hypertension control. CONCLUSIONS: Effective hypertension control reduced the incidence of chronic kidney disease and adverse outcomes of End Stage Renal Disease. The strategy both improves health outcomes of CKD and saves money. More public health efforts should be directed to improve the hypertension awareness and control as one effective chronic kidney disease prevention strategy.
PUK18 RENAL TRANSPLANTATION VS HEMODIALYSIS-COST EFFECTIVENESS ANALYSIS
Perovich S Serbian Medical Society-Health Management Committee, Belgrade, Serbia and Montenegro OBJECTIVES: Dialysis treatments are performed in 4100 patients in Serbia. At endstage renal disease (ESRD)the only correct selection is kidney transplatation. The basic aim of research was to compare ratio of costs and effects (CEA) of hemodialysis and kidney transplatation in patients at ESRD.It is assumed, that in spite of that kidney transplatation is being more desirable than hemodialysis from aspect of lower costs and better quality of patient's life, number of transplantations in Serbia is still modest with respect to requirements. METHODS: The life quality was measured by validated McGill Questionary. Research has included 150 patients totally, divided in two groups: 1) Study group including 50 patients having kidney transplantation performed at Clinical Centre of Serbia; and 2) Control Group including 100 patients on hemodialysis at six different Clinical Centres, comparable with respect to sex, age and length of treatment with Study group. RESULTS: Effect of kidney transplantation in relation to hemodialysis being selection of treatment is expressed in form of incremental ratio of costs and effects (ICER). It is clearly evident that the strategy of kidney transplantation is far more profitable considering the fact that it represents saving of 3132,256.25 per one year of contribution QALY within the period of 10 years. According to all aspects of live quality (physical symptoms and problems, physical well-being, phychological symptoms, existential well-being and support), difference is statistically important in favour of transplant patents. CONCLUSIONS: Out of the effected cost calculation it is evident that the costs of patient treatment therapy by hemodialysis at end-stage renal disease is far greater than by performing therapy of transplantation and maintenance, by almost three and a half times (3.38). Difference in total aspects of human life (physical, emotional, social, spiritual and financial) between dialysed and transplant patients is statistically important and by 18.12% greater in transplant patients than in patients being on hemodialysis. We used a simple decision-tree model, a third payer perspective with only direct costs included, and a one-year timeline (with no discount). The model incorporated 20 variables, including costs obtained from local sources (databases of more than ten thousand patients) and epidemiological data both from international published literature, and Colombian databases (particularly for treatment-related complications). Utilities (in QALY) were obtained from Tufts CEA Registry and discussed with local experts and patient panels (for an average of 0.6375 QALY for PD and 0.5950 for HD). RESULTS:
PUK19 ECONOMIC EVALUATION OF PERITONEAL DIALYSYS COMPARED WITH HEMODIALYSIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE SECONDARY TO DIABETES OR HYPERTENSION IN COLOMBIA
We estimate that the average annual cost of PD in Colombia in 2008 was US$16,747 (at September 2009 official exchange rate of Col$2066 per dollar) while HD costs on average US$18,199 per year, including in both cases direct costs of treatment-related complications but not other disease-related events. Average cost of each QALY gained in a dialysis patient in Colombia ranges from US$26,300 in PD to US$30,600 in HD. In our sample, PD was also associated with a reduced frequency of hospitalization and shorter hospital stays than HD (on average, 5.2 and 6.5 hospital days per year, respectively). CONCLUSIONS: In Colombia, costs of KRT are around two times the suggested cost-effectiveness threshold of three times the per capita GDP. On average, and perhaps in part attributable to different case mix, PD is dominant over HD. The model is highly sensitive to patients preferences (expressed in our case in QALYs), which suggest PD is particularly valued in independence seeking patients.
PUK20 ECONOMIC EVALUATION OF THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN COLOMBIA
Gómez P 1 , Plata M 2 , Carreño A 2 , Guzmán F 2 , Jiménez LA 3 , Calderón C 4 , Rosselli D 5 1 Universidad Nacional de Colombia, Bogota, DC, Colombia, 2 Fundación Santa Fe de Bogotá, Bogota, DC, Colombia, 3 GSK, Bogota, DC, Colombia, 4 Independent consultant, Bogota, DC, Colombia, 5 Universidad Jorge Tadeo Lozano, Bogota, DC, Colombia OBJECTIVES: Benign prostatic hyperplasia has a high prevalence and represents an important burden on the quality of life of the affected patients. New medical interventions have been added to the more traditional surgical approach. This Markov costutility and cost-effectiveness model, adjusted to the Colombian health care environment, represents the decision to treat a hypothetical 60-year-old patient either with surgery (transurethral resection or TUR) or with either alpha blockers (αB), 5 alpha reductase inhibitors (5ARI) or combined therapy (CT). METHODS: We used a third party payer perspective, as well as a 5-year timeframe. Effectiveness data were taken from international clinical trials, surgical complications were those of the AUA (American Urological Association) practice guidelines. All costs were local, combining Colombian Social Security Institute prices as well as real costs from a local private clinic. Utilities and disutilities were measured in QALY, obtained from Tufts CEA registry. Discount rate was 5% for costs and QALYs. RESULTS: The model shows that, over the 5-year timeframe, surgery has the lowest average overall cost (US$1573 at September 2009 official exchange rate of Col$2066 per US$), compared with αB (US$3916), 5ARI (US$3156) or CT (US$5232). With respect to surgery, treatment with 5ARI is the most cost-effective (US$8426 per additional QALY gained) followed by CT (US$12099 per QALY) and αB (US$24,695). Cost per surgery averted was US$1810 with 5ARI, US$2531 with αB and US$3935 with CT. CONCLUSIONS: We conclude that treatment with 5ARI is "cost-effective" according to international standards (less than three times per capita GDP paid for each additional QALY gained). The incremental cost-utility ratio of CT is highly sensitive to price of therapy; if price of CT were equal to the price of 5ARI, the cost of each additional QALY gained would be US$2733.
